Clinical trial
Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
NCT00097344 is registered in ClinicalTrials.gov with Intarcia Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
- Lead sponsor
- Intarcia Therapeutics
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 31, 2004
- Completion date
- August 31, 2006
- Enrollment
- 842
- Sites
- 104
Conditions
As the registry lists them; a condition with its own page is linked.